Gain Therapeutics, Inc.

NasdaqGM GANX

Gain Therapeutics, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 851.42

Gain Therapeutics, Inc. Price to Sales Ratio (P/S) is 851.42 on January 14, 2025, a 72.73% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Gain Therapeutics, Inc. 52-week high Price to Sales Ratio (P/S) is 1,078.33 on January 06, 2025, which is 26.65% above the current Price to Sales Ratio (P/S).
Gain Therapeutics, Inc. 52-week low Price to Sales Ratio (P/S) is 277.52 on August 13, 2024, which is -67.41% below the current Price to Sales Ratio (P/S).
Gain Therapeutics, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 592.99.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: GANX

Gain Therapeutics, Inc.

CEO	Mr. Gene Mack M.B.A.
IPO Date	March 19, 2021
Location	United States
Headquarters	4800 Montgomery Lane
Employees	29
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Key trends

Past 5 years